Ahmed O Elzoghby1,2, Sarah A El-Lakany2, Maged W Helmy1,3, Marwa M Abu-Serie4, Nazik A Elgindy2. 1. Cancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt. 2. Department of Industrial Pharmacy, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt. 3. Department of Pharmacology & Toxicology, Faculty of Pharmacy, Damanhour University, Damanhour, Egypt. 4. Medical Biotechnology Department, Genetic Engineering & Biotechnology Research Institute, City of Scientific Research & Technological Applications, New-Borg El-Arab City, Alexandria 21934, Egypt.
Abstract
AIM: Oral administration of exemestane (EXM) and resveratrol (RES) for breast cancer therapy has been limited by their poor solubility and low permeability. METHODS: In this study, these issues were tackled using zein nanocapsules (ZNCs) for oral EXM/RES codelivery combining drug solubilization within oily core and resistance to digestion via hydrophobic protein shell. Furthermore, higher oral stability and sustained release could be enabled by glutaraldehyde crosslinking of zein shell. RESULTS & CONCLUSION: EXM/RES-ZNCs showed enhanced cytotoxicity against MCF-7 and 4T1 breast cancer cells compared with free drug combination with higher selectivity to cancer cells rather than normal fibroblasts. In vivo, crosslinked EXM/RES-ZNCs markedly reduced the percentage increase of Ehrlich ascites mammary tumor volume in mice by 2.4-fold compared with free drug combination.
AIM: Oral administration of exemestane (EXM) and resveratrol (RES) for breast cancer therapy has been limited by their poor solubility and low permeability. METHODS: In this study, these issues were tackled using zein nanocapsules (ZNCs) for oral EXM/RES codelivery combining drug solubilization within oily core and resistance to digestion via hydrophobic protein shell. Furthermore, higher oral stability and sustained release could be enabled by glutaraldehyde crosslinking of zein shell. RESULTS & CONCLUSION: EXM/RES-ZNCs showed enhanced cytotoxicity against MCF-7 and 4T1 breast cancer cells compared with free drug combination with higher selectivity to cancer cells rather than normal fibroblasts. In vivo, crosslinked EXM/RES-ZNCs markedly reduced the percentage increase of Ehrlich ascites mammary tumor volume in mice by 2.4-fold compared with free drug combination.
Entities:
Keywords:
breast cancer; combined therapy; exemestane; oral delivery; resveratrol; zein nanocapsules
Authors: Sarah Mokhtar; Sherine N Khattab; Kadria A Elkhodairy; Mohamed Teleb; Adnan A Bekhit; Ahmed O Elzoghby; Marwa A Sallam Journal: Front Chem Date: 2022-03-22 Impact factor: 5.221
Authors: Sarah A El-Lakany; Ahmed I Abd-Elhamid; Elbadawy A Kamoun; Esmail M El-Fakharany; Wael M Samy; Nazik A Elgindy Journal: Int J Nanomedicine Date: 2019-10-16
Authors: Manjusha Annaji; Ishwor Poudel; Sai H S Boddu; Robert D Arnold; Amit K Tiwari; R Jayachandra Babu Journal: Cancer Rep (Hoboken) Date: 2021-03-02
Authors: Maan T Khayat; Mohamed A Zarka; Dalia Farag A El-Telbany; Ali M El-Halawany; Hussam Ibrahim Kutbi; Walid F Elkhatib; Ayman M Noreddin; Ahdab N Khayyat; Rania Farag A El-Telbany; Sherif F Hammad; Ashraf B Abdel-Naim; Ebtesam M Alolayan; Majid Mohammad Al-Sawahli Journal: Sci Rep Date: 2022-09-08 Impact factor: 4.996